> ## Content Index
> Fetch the complete content index at: https://www.coios.me/llms.txt
> Use this file to discover other available public pages before exploring further.

# Rheumatic heart disease valves show B-cell activity, and rituximab is tested in children
- URL: https://www.coios.me/rheumatic-heart-disease-valves-show-b-cell-activity-and/
- Published: 2026-11-18T13:02:20.000Z
- Updated: 2026-11-18T14:02:21.000Z
- Description: Rheumatic mitral valves showed raised B-cell pathways, and rituximab was well tolerated in children with rheumatic heart disease in Senegal.
- Author: Daniel Ryan
- Tags: Tomorrow's world, Innovation in treatment, Senegal, #preprint, #new, #item, #source-2026-11, #score-62

The study examined B cells as a possible treatment target in rheumatic heart disease (RHD). A 750-mRNA panel on rheumatic mitral valve tissue showed upregulated B-cell pathways, including CD20-associated and immunoglobulin genes. Children with RHD in Dakar, Senegal, then received rituximab in a feasibility study, and treatment was well tolerated. In a first-year safety analysis of the later randomised trial, treated children had falling anti-streptolysin O titres. They also showed clinical improvement compared with controls. The abstract gives no participant numbers or effect sizes, and the trial findings are preliminary.

*Why it is interesting: No current therapy targets the autoimmune process behind rheumatic heart disease. This study links valve tissue findings to an early trial of B-cell depletion in children in Senegal.*

Source

[medRxiv, 17 November 2026](https://doi.org/10.64898/2026.11.17.26367998?ref=coios.me)

DOI

10.64898/2026.11.17.26367998

Type

Preprint

Design

Valve tissue transcriptomic panel (750 mRNAs) plus rituximab feasibility study and first-year interim safety analysis of an RCT in children with RHD, Dakar; n and follow-up not stated

Verdict

New finding

Driver

[Innovation in treatment](https://www.coios.me/d-treatment-innovation/)